Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Upadacitinib

FDA-approved product (tablet, extended release, oral), marketed as Rinvoq, Rinvoq Lq.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Upadacitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Upadacitinib. Its therapeutic class is shown instead.

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Upadacitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Upadacitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

    NCT06498167 · start 2024-07-01

    Registered record
    Registry ID
    NCT06498167
    Conditions
    Inflammatory Disease; Drug Side Effect; Drug Use; Adverse Drug Event; Adverse Drug Reaction; Safety Issues
    Interventions
    Upadacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-07-01
    Completion
    2024-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Disease; Drug Side Effect; Drug Use; Adverse Drug Event +2 more
    InterventionUpadacitinib
    PhaseNot recorded
    Registry statusUnknown

  • Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease

    NCT06459297 · start 2024-06-24

    Registered record
    Registry ID
    NCT06459297
    Conditions
    Ulcerative Colitis; Crohn's Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-06-24
    Completion
    2025-12-09
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis; Crohn's Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China

    NCT06421740 · start 2024-06-07

    Registered record
    Registry ID
    NCT06421740
    Conditions
    Atopic Dermatitis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-06-07
    Completion
    2026-05-25
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

    NCT06379958 · start 2024-04-08

    Registered record
    Registry ID
    NCT06379958
    Conditions
    Pharmacokinetics
    Interventions
    leramistat 40mg; Itraconazole 200 mg; Phenytoin 100 Mg Oral Capsule; Simvastatin 40mg; Upadacitinib 15 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-04-08
    Completion
    2024-09-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    Interventionleramistat 40mg; Itraconazole 200 mg; Phenytoin 100 Mg Oral Capsule; Simvastatin 40mg +1 more
    PhasePhase 1
    Registry statusUnknown

  • Ibd CAncer and seRious Infections in France (I-CARE 2)

    NCT06089590 · start 2024-01-25

    Registered record
    Registry ID
    NCT06089590
    Conditions
    IBD; Ulcerative Colitis; Crohn Disease
    Interventions
    Non-interventional
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-01-25
    Completion
    2031-03-01
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIBD; Ulcerative Colitis; Crohn Disease
    InterventionNon-interventional
    PhaseNot recorded
    Registry statusRecruiting

  • Upadacitinib for Refractory Behcet's Syndrome

    NCT07080346 · start 2024-01-25

    Registered record
    Registry ID
    NCT07080346
    Conditions
    Behcet Syndrome
    Interventions
    Upadacitinib 15 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-01-25
    Completion
    2025-07-08
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBehcet Syndrome
    InterventionUpadacitinib 15 MG
    PhasePhase 2
    Registry statusCompleted

  • Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis

    NCT07386717 · start 2024-01-01

    Registered record
    Registry ID
    NCT07386717
    Conditions
    Psoriatic Arthritis; Upadacitinib; Interleukin-17 Inhibitors
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-01-01
    Completion
    2025-12-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriatic Arthritis; Upadacitinib; Interleukin-17 Inhibitors
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

    NCT05782907 · start 2023-11-06

    Registered record
    Registry ID
    NCT05782907
    Conditions
    Ulcerative Colitis
    Interventions
    Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-11-06
    Completion
    2031-10
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionUpadacitinib
    PhasePhase 3
    Registry statusActive not recruiting

  • Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

    NCT05959083 · start 2023-08-18

    Registered record
    Registry ID
    NCT05959083
    Conditions
    Atopic Dermatitis (AD)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-08-18
    Completion
    2026-05-07
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis (AD)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan

    NCT06023030 · start 2023-07-28

    Registered record
    Registry ID
    NCT06023030
    Conditions
    Crohn's Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-07-28
    Completion
    2027-05
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease

    NCT07697547 · start 2023-07-01

    Registered record
    Registry ID
    NCT07697547
    Conditions
    Inflammatory Bowel Disease (IBD); Crohn's Disease
    Interventions
    Upadacitinib; Ustekinumab (UST)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-07-01
    Completion
    2026-03-31
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Bowel Disease (IBD); Crohn's Disease
    InterventionUpadacitinib; Ustekinumab (UST)
    PhaseNot recorded
    Registry statusCompleted

  • Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

    NCT05814627 · start 2023-06-15

    Registered record
    Registry ID
    NCT05814627
    Conditions
    Rheumatoid Arthritis
    Interventions
    Upadacitinib; Adalimumab; Upadacitinib Matching Placebo; Adalimumab Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-06-15
    Completion
    2026-07-15
    Enrolment
    487

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionUpadacitinib; Adalimumab; Upadacitinib Matching Placebo; Adalimumab Matching Placebo
    PhasePhase 3
    Registry statusCompleted

  • NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study

    NCT06956703 · start 2022-12-12

    Registered record
    Registry ID
    NCT06956703
    Conditions
    Gastro-Intestinal Disorder; Crohn Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-12-12
    Completion
    2027-12-31
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastro-Intestinal Disorder; Crohn Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

    NCT05494606 · start 2022-08-15

    Registered record
    Registry ID
    NCT05494606
    Conditions
    Ulcerative Colitis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-08-15
    Completion
    2028-03
    Enrolment
    785

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

    NCT05094128 · start 2021-11-22

    Registered record
    Registry ID
    NCT05094128
    Conditions
    Axial Spondylarthritis (r-axSpA)
    Interventions
    Upadacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-11-22
    Completion
    2027-04
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAxial Spondylarthritis (r-axSpA)
    InterventionUpadacitinib
    PhaseNot recorded
    Registry statusActive not recruiting